Aluminum Chloride
證據等級: L5 | 預測適應症: 10 個
## 藥師評估報告
Aluminum Chloride：從止汗劑到皮膚疾病的潛在擴展
一句話總結
Aluminum chloride 主要用作止汗劑和牙科止血劑，TxGNN 預測其可能對脂漏性角化症、脂漏性皮膚炎及多汗症相關皮膚病有治療潛力。
快速總覽
| 項目 | 內容 |
|---|---|
| 原適應症 | 抗多汗、牙齦止血、牙齦收斂 |
| 預測新適應症 | 脂漏性角化症、脂漏性皮膚炎、痤瘡、皮膚疾病（多汗相關） |
| TxGNN 預測分數 | 0.997（脂漏性角化症）、0.996（脂漏性皮膚炎） |
| 證據等級 | L3-L4（有文獻支持，多汗症治療） |
| 台灣上市 | 已上市 |
| 許可證數 | 4 張（目前有效 1 張） |
| 建議決策 | Hold |
預測適應症詳細分析
1. seborrheic keratosis L5 99.68% 主要分析
為什麼這個預測合理？
Aluminum chloride 的主要作用機轉是阻塞汗腺管道並造成局部蛋白質沉澱，具有收斂和止血作用。
預測的機轉分析：
- 脂漏性角化症 / 脂漏性皮膚炎：這些預測的關聯性較弱。雖然 aluminum chloride 具有局部收斂作用，但目前沒有機轉上的明確支持顯示其對這些角化或發炎性疾病有效。
- 皮膚疾病（多汗症相關）：這是 aluminum chloride 的核心適應症。文獻顯示：
- 20% aluminum chloride 溶液是多汗症的一線治療
- 可用於腋下、手掌、足底多汗症
- 也可用於殘肢多汗症的治療
- 痤瘡：aluminum chloride 可能通過其收斂作用減少皮脂分泌，但這不是其主要用途。
臨床試驗
目前無針對此特定適應症的臨床試驗登記。
2. congenital prothrombin deficiency L5 99.66%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
3. seborrheic dermatitis L5 99.63%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
4. acne (disease) L5 99.43%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
5. vulvar inverted follicular keratosis L5 99.38%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
6. skin disease L1 99.35%
臨床試驗（20 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT03416348 | PHASE1 | COMPLETED | 95 | Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Tr... |
| NCT02661490 | PHASE2 | COMPLETED | 320 | A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovir... |
| NCT00509886 | NA | COMPLETED | 24 | Non-prescription Versus Prescription Topical Treatments Versus no Treatment in t... |
| NCT03731988 | PHASE4 | COMPLETED | 47 | A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic ... |
| NCT05501444 | NA | COMPLETED | 7 | Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Us... |
| NCT03236012 | PHASE1 | COMPLETED | 25 | Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Tr... |
| NCT02142504 | PHASE2 | COMPLETED | 454 | Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicit... |
| NCT03433859 | PHASE3 | COMPLETED | 54 | Prospective Multicentric Open Randomised Controlled Trial Comparing Topical Alum... |
| NCT01459393 | PHASE3 | COMPLETED | 137 | Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in... |
| NCT02028208 | PHASE2 | COMPLETED | 56 | Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Do... |
| NCT06881394 | NA | RECRUITING | 30 | A Pilot, Open-Label, Single Site Study Evaluating the Safety and Efficacy of Top... |
| NCT03250533 | NA | UNKNOWN | 52 | Analysis of the Effects of Phototherapy With Light-emitting Diodes (LED) and Ele... |
| NCT00429780 | PHASE2, PHASE3 | COMPLETED | 100 | A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania M... |
| NCT02639351 | PHASE1 | COMPLETED | 80 | A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the S... |
| NCT02248298 | PHASE1 | COMPLETED | 93 | Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy With Short I... |
| NCT06800131 | PHASE1 | NOT_YET_RECRUITING | 40 | A Phase I, Randomized, Open-Label, Active-Control Study to Evaluate Safety, Tole... |
| NCT04826094 | PHASE1 | COMPLETED | 143 | A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenici... |
| NCT05876195 | NA | UNKNOWN | 39 | Varying Keyhole Limpet Haemocyanin-adjuvant Dose Combinations to Explore the Imm... |
| NCT00429715 | PHASE2, PHASE3 | COMPLETED | 150 | A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania M... |
| NCT06748404 | PHASE2 | RECRUITING | 28 | A Phase 2 Randomized Study of TriCalm Hydrogel® in the Treatment of Immunotherap... |
相關文獻（19 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 30215934 | 2018 | Article | American family physician | Hyperhidrosis: Management Options. |
| 30710603 | 2019 | Article | Journal of the American Academ | The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review... |
| 26649952 | 2015 | Article | Praxis | [Hyperhidrosis]. |
| 37142953 | 2023 | Article | BMC cancer | Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin re... |
| 31567135 | 2020 | Article | The American Journal of dermat | Aluminum Chloride-Induced Apoptosis Leads to Keratinization Arrest and Granular ... |
| 12030870 | 2002 | Article | Dermatologic surgery : officia | Skin barrier changes induced by aluminum oxide and sodium chloride microdermabra... |
| 15088261 | 2003 | Article | Seminars in neurology | Disorders of sweating. |
| 35029347 | 2022 | Article | Dermatitis : contact, atopic, | Aluminum-Allergen of the Year 2022. |
| 3134977 | 1988 | Article | British medical journal (Clini | Treating hyperhidrosis. |
| 12471696 | 2002 | Article | Current problems in dermatolog | Topical pharmacological treatment. |
| 37104962 | 2023 | Article | Biomaterials advances | Assessment of antibacterial properties and skin irritation potential of anodized... |
| 30640770 | 2019 | Article | Dermatologic surgery : officia | Topical Aluminum Chloride and Monsel's Solution Block Toluidine Blue Staining in... |
| 24552408 | 2013 | Article | Dermatologic therapy | Update on pediatric hyperhidrosis. |
| 32990370 | 2020 | Article | Dermatologic therapy | Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum ch... |
| 27215162 | 2016 | Article | Clinics in podiatric medicine | Plantar Hyperhidrosis: An Overview. |
| 11260552 | 2001 | Article | Journal of the American Academ | Aquagenic palmoplantar keratoderma. |
| 40396355 | 2025 | Article | Journal of cutaneous medicine | A Comparative Study of Aluminum Chloride, Oxybutynin Chloride, and Botulinum Tox... |
| 36495093 | 2022 | Article | Journal der Deutschen Dermatol | Comparison of a novel aluminum lactate-based with an aluminum chloride-based ant... |
| 3771053 | 1986 | Article | International journal of derma | Frey's syndrome. |
7. dry eye syndrome L4 99.31%
相關文獻（1 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 34942465 | 2022 | Article | Colloids and surfaces. B, Bioi | Formulation and development of tacrolimus-gellan gum nanoformulation for treatme... |
8. eye disease L3 99.29%
臨床試驗（1 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT07122297 | NA | COMPLETED | 52 | Clinical Evaluation of Different Gingival Displacement Methods |
相關文獻（12 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 34942465 | 2022 | Article | Colloids and surfaces. B, Bioi | Formulation and development of tacrolimus-gellan gum nanoformulation for treatme... |
| 37035098 | 2023 | Article | International journal of Alzhe | Prognosis of Biomarker of Alzheimer's Disease in the Function of the Retina and ... |
| 15150681 | 2004 | Article | Archives of toxicology | Mitochondrial viability and apoptosis induced by aluminum, mercuric mercury and ... |
| 39257107 | 2024 | Article | Clinical laboratory | A Case of Ocular Infection with Clostridium tertium Caused by a Salute Gun Explo... |
| 22115621 | 2012 | Article | Pharmacology, biochemistry, an | Neurobehavioral toxic effects of perinatal oral exposure to aluminum on the deve... |
| 25090044 | 2015 | Article | Retina (Philadelphia, Pa.) | Imaging characteristics of intraocular foreign bodies: a comparative study of pl... |
| 23146184 | 2012 | Article | Applied spectroscopy | Evaluation of laser-induced breakdown spectroscopy (LIBS) for measurement of sil... |
| 37062685 | 2023 | Article | Wei sheng yan jiu = Journal of | [Change of drinking water quality in Shijiazhuang South-to-North Water Diversion... |
| 18378229 | 2008 | Article | Experimental eye research | Comparative efficacy of topical antihistamines in an animal model of early phase... |
| 5396686 | 1969 | Article | Oftalmologicheskii zhurnal | [Local action of basic aluminum chloride in experimental infectious conjunctivit... |
| 8000497 | 1994 | Article | Occupational and environmental | Upper airway irritation and small airways hyperreactivity due to exposure to pot... |
| 5516475 | 1970 | Article | Oftalmologicheskii zhurnal | [Preliminary results of the treatment of chronic conjunctivitis with an aqueous ... |
9. von Hippel anomaly L5 99.18%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
10. chronic relapsing inflammatory optic neuropathy L5 99.16%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
台灣上市資訊
| 許可證號 | 品名 | 劑型 | 核准適應症 | 狀態 |
|---|---|---|---|---|
| 衛署藥製字第043123號 | 克狐止汗劑（汎生） | 外用液劑 | 抗多汗 | 有效 |
| 衛署藥輸字第009331號 | 牙齦止血液 | 牙科用液劑 | 牙齦止血 | 已註銷 |
| 衛署藥輸字第009332號 | 牙齦收縮止血劑 | 壓排線劑 | 牙齦止血 | 已註銷 |
| 內衛藥製字第009014號 | 純露糖漿 | 糖漿劑 | 緩解感冒症狀 | 已註銷 |
目前有效許可證持有者：臺灣汎生製藥廠股份有限公司
安全性考量
- 局部副作用：
- 皮膚刺激、燒灼感
- 接觸性皮膚炎
- 皮膚乾燥
- 特殊考量：
- 不可用於破損皮膚
- 建議於睡前使用，待乾燥後再穿著衣物
- 過敏體質者需小心使用
- 2022 年被列為「年度過敏原」，需注意鋁過敏可能性
- 藥物交互作用：無已知重要交互作用
安全性資訊請參考原廠仿單。
結論與下一步
決策：Hold
理由： TxGNN 預測的新適應症（脂漏性角化症、脂漏性皮膚炎）缺乏機轉上的合理性支持。Aluminum chloride 的收斂作用與這些疾病的病理生理學關聯不明確。
然而，對於多汗症相關皮膚問題，aluminum chloride 已經是確立的一線治療選擇，這部分的預測是準確的。
若考慮進一步探索需要：
- 釐清脂漏性疾病預測的機轉依據
- 考量是否為「信號雜訊」而非真正的藥物-疾病關聯
- 目前資料不足以支持臨床試驗
現有確立用途：
- 局部多汗症一線治療
- 手術後殘肢多汗症
- 牙科局部止血（雖台灣已無相關許可證）
不建議用於：脂漏性角化症或脂漏性皮膚炎的治療，除非有更多機轉證據支持。
相關藥物報告
- Scopolamine - 證據等級 L5
- Potassium Iodide - 證據等級 L5
- Paclitaxel - 證據等級 L5
- Denosumab - 證據等級 L5
- Butenafine - 證據等級 L5
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
引用本報告
如需引用本報告，請使用以下格式：
APA 格式：
TwTxGNN. (2026). Aluminum Chloride老藥新用驗證報告. https://twtxgnn.yao.care/drugs/aluminum_chloride/
BibTeX 格式：
@misc{twtxgnn_aluminum_chloride,
title = {Aluminum Chloride老藥新用驗證報告},
author = {TwTxGNN Team},
year = {2026},
url = {https://twtxgnn.yao.care/drugs/aluminum_chloride/}
}
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。